Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LBRX
SellLB Pharmaceuticals Inc · Healthcare · United States · $1.5B · Avg Vol: $17M/d
COMPANY DESCRIPTION
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for central nervous system disorders. The company's lead candidate, LB-102, is being investigated for schizophrenia, targeting a new mechanism of action. LB Pharmaceuticals aims to address the significant need for improved therapies in psychiatric conditions through its innovative drug discovery efforts.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -4.05 | -1.77 | -17.82 | -3.13 | — | -5.10 | -5.54 | -5.04 | — |
| Shares | 22.4M | 22.4M | 22.4M | 25.3M | +12.7% | 32.3M | — | — | — |
| Debt | 24.1M | 0 | 3.7M | 3.6M | -47.1% | 5.2M | — | — | — |
| Equity | -28.8M | -34.5M | -94.6M | 301.3M | — | — | — | — | — |
| Op CF | -2.7M | -12.1M | -53.1M | -35.2M | — | -82.4M | — | — | — |
| Inv CF | 0.1M | -28.0M | 23.2M | -39.9M | — | — | — | — | — |
| Fin CF | 23.0M | 33.7M | 38.3M | 302.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LBRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LBRX | LB Pharmaceuticals Inc(you) | $1.5B | 34 | Sell |
| BCAX | Bicara Therapeutics Inc. | $1.6B | 34 | Sell |
| ANAB | AnaptysBio, Inc. | $1.7B | 34 | Sell |
| ANRO | Alto Neuroscience, Inc. | $1.4B | 32 | Sell |
| FBRX | Forte Biosciences, Inc. | $1.6B | 39 | Hold |
| VIR | Vir Biotechnology, Inc. | $1.8B | 31 | Sell |
| ZYME | Zymeworks Inc. | $2.0B | 33 | Sell |
| APMD | Apnimed, Inc. | $1.2B | 36 | Hold |
| XNCR | Xencor, Inc. | $1.9B | 31 | Sell |
| AGIO | Agios Pharmaceuticals, Inc. | $2.0B | 31 | Sell |
Peer medians: ROE -24.4% · P/E 31.0x · Gross margin 58.8%